[Long-term experience with prophylactic BCG therapy of high risk patients with superficial bladder tumors].
The authors analysed the data of 45 high risk patients with recurrent superficial transitional cell cancer of the bladder who received after radical transurethral resection prophylactic intracavitaly BCG treatment among 1987-1995. They observed complete remission (28/45), partial remission (10/45), non responders (7/45). The progression rate was (12/45). In case of recurrence they made a second cure with high dose BCG. They deemed the maintenance therapy useful. They reviewed their experiences with the patients who had a B2 stage before. They gave account of their result after complementary chemotherapy with Pallagicin. One serious pulmonary side effect, was detected, which had been treated successfully with antituberculotic drugs.
Prekopp
G
G
Fövárosi Onkormányzat Bajcsy-Zsilinszky Kórház-Rendelöintézet, Budapest.
Kiss
T
T
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008297:Male; D011315:Preventive Medicine; D011468:Prostatectomy; D012307:Risk Factors; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine
Fokozott kockázatú felületes hólyagtumoros betegek profilaktikus intravesicalis BCG-kezelésével szerzett hosszú távú tapasztalataink.